COMMUNIQUÉS West-GlobeNewswire

-
Candel Therapeutics Expands Russell Index Presence with Addition to Multiple Value-Oriented Indexes in 2025 Reconstitution
09/07/2025 -
MaxCyte to Report Second Quarter 2025 Financial Results on August 6, 2025
09/07/2025 -
New Clinical Findings Published in Scientific Journal Nature Validate LIXTE’s Ongoing Ovarian and Colorectal Cancer Trials
09/07/2025 -
The Anosh Foundation Launches Global Oversight Initiative to Strengthen COVID-19 Testing and Vaccination Integrity
09/07/2025 -
Revolution Medicines and Iambic Announce Technology and Research Collaboration Using Iambic’s AI Discovery Tools to Pursue New Drug Candidates
09/07/2025 -
Dr. Anosh Ahmed Plans $25,000 Donation to Support FBI Families and Law Enforcement Mental Health Programs
09/07/2025 -
Jasper Therapeutics Announces Corporate Reorganization and Other Cost Cutting Measures to Extend Cash Runway
09/07/2025 -
BioVie Announces Data Highlighting Bezisterim’s Potential to Slow or Reverse Biological Aging and Neurodegeneration Featured as a Keynote Talk at the 7th World Aging and Rejuvenation Conference
09/07/2025 -
Amneal to Report Second Quarter 2025 Results on August 5, 2025
09/07/2025 -
Galectin Therapeutics Announces New $10 Million Credit Line from Richard E. Uihlein, Sufficient to Cover Expected Expenditures Through June 2026
09/07/2025 -
FluidForm Bio™ Presents Six-Month Efficacy Data of FRESH 3D Bioprinted Human Islet Subcutaneous Scaffolds at the American Diabetes Association (ADA) 85th Scientific Sessions
09/07/2025 -
Benitec Biopharma Provides Operational Updates
09/07/2025 -
TerrAscend Completes $79 Million Non-Dilutive Debt Financing
09/07/2025 -
DIMERx Appoints Biotech Leader Sergio Traversa, PharmD, to Board of Directors
09/07/2025 -
Werewolf Therapeutics to Participate in the KidneyCAN 7th Annual Kidney Cancer Research Summit
09/07/2025 -
ImmuCell Announces Preliminary, Unaudited Sales Results for Q2 of 2025
09/07/2025 -
Rhythm Pharmaceuticals Announces Oral MC4R Agonist Bivamelagon Achieved Statistically Significant, Clinically Meaningful BMI Reductions in Placebo-controlled Phase 2 Trial in Acquired Hypothalamic Obesity
09/07/2025 -
KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)
09/07/2025 -
Artelo Biosciences Announces Positive Preclinical Efficacy Data for ART26.12 in Osteoarthritis Pain at the 35th Annual International Cannabinoid Research Society Symposium
09/07/2025
Pages